Adalimumab Monoclonal Antibody
Adalimumab is a fully human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) and is used to treat autoimmune conditions such as rheumatoid arthritis and Crohn's disease. This product is imported in bulk, unmixed form, not put up in measured doses or retail packaging, which qualifies it under tariff item 3002.13.00 as an immunological product.
Import Duty Rates by Country of Origin
| Origin Country | MFN Tariff | Surtaxes | Total Effective Rate |
|---|---|---|---|
| 🇨🇳China | Free | — | Free |
| 🇲🇽Mexico | Free | — | Free |
| 🇺🇸United States | Free | — | Free |
| 🇩🇪Germany | Free | — | Free |
| 🇯🇵Japan | Free | — | Free |
More Specific Codes
This product may fall under a more specific subheading:
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If the product is mixed with stabilizers or other additives for preservation
Subheading 3002.15 covers mixed immunological products, whereas 3002.13.00 is limited to unmixed products.
If the product is put up in measured doses or in forms or packings for retail sale
Medicaments put up for retail sale fall under heading 30.04, not 30.02.
If the product is an antiserum rather than a monoclonal antibody
Antisera are classified separately from other immunological products under subheading 3002.12.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right tariff item — and can price the duty on it in the same conversation.
Import Tips & Compliance
• Ensure the product is imported as a single, unmixed substance without stabilizers or additives, as these may shift classification
• Maintain detailed documentation proving biotechnological production and absence of retail packaging to support the tariff classification
• Verify whether a Drug Establishment Licence from Health Canada is required for the import
Related Products under Tariff item 3002.13.00
Adalimumab High-Concentration Solution
Adalimumab high-concentration solution is a fully human monoclonal antibody against TNF-alpha, used for autoimmune diseases like psoriasis. As an aqueous solution of an unmixed product, it is treated as unmixed under chapter note 3(a)(1) and qualifies for tariff item 3002.13.00.
Atezolizumab Monoclonal Antibody
Atezolizumab is a humanized IgG1 monoclonal antibody that blocks PD-L1 and is used in the treatment of bladder cancer and other malignancies. Imported as an unmixed bulk substance without measured doses or retail packaging, it falls under tariff item 3002.13.00 as an immunological product obtained by biotechnological processes.
Bevacizumab Monoclonal Antibody
Bevacizumab is a humanized monoclonal antibody that binds vascular endothelial growth factor (VEGF) and is used to treat colorectal and lung cancers. This bulk, unmixed product is not in measured doses or retail packaging, making it classifiable under tariff item 3002.13.00 as an immunological product.
Blinatumomab Monoclonal Antibody
Blinatumomab is a bispecific T-cell engager (BiTE) monoclonal antibody used for the treatment of acute lymphoblastic leukemia. As an unmixed biotechnological product not put up in measured doses or retail sale forms, it is classified under tariff item 3002.13.00.
Bulk Colony Stimulating Factor G-CSF
Bulk Colony Stimulating Factor G-CSF (Filgrastim) is a recombinant protein that stimulates neutrophil production, primarily used post-chemotherapy. It is an unmixed immunological product, not put up in measured doses or for retail sale, and is classified under tariff item 3002.13.00 as per Chapter 30 Note 2, which covers colony stimulating factors.
Bulk Filgrastim
Bulk Filgrastim is a recombinant granulocyte colony-stimulating factor (G-CSF) analog that stimulates the production of neutrophils. It is an unmixed immunological product, not put up in measured doses or retail packaging, and is intended for further formulation. It falls under tariff item 3002.13.00 as a hematopoietin directly involved in the regulation of immunological processes.